510(k) vs PMA: Which FDA Pathway Does Your Device Need?

The FDA regulatory pathway for a medical device is determined primarily by two factors: device classification and the availability of a valid predicate. Getting this wrong early — pursuing a 510(k) for a device that requires a PMA, or spending months on a De Novo when a simple 510(k) would do — is an expensive mistake.

The three pathways

510(k) Premarket Notification is the most common route. It applies to Class II devices where a valid predicate exists. The legal standard is substantial equivalence. Average FDA review time is 3-6 months for a standard 510(k).

Premarket Approval (PMA) applies to Class III devices — those that support or sustain human life or present a potential unreasonable risk. PMA requires valid scientific evidence, typically clinical trials. Average review time is 180 days from acceptance, though the full process commonly takes 2-4 years.

De Novo is for novel, low-to-moderate risk devices with no valid predicate. It establishes a new device type and, once granted, the device can serve as a predicate for future 510(k)s. De Novo review typically takes 12-24 months.

How FDA classification works

• Class I — General controls only. Low risk. Most are exempt from premarket notification. About 47% of devices.
• Class II — General and special controls. Moderate risk. Most require 510(k) clearance. About 43% of devices.
• Class III — General controls and PMA. High risk, life-sustaining or life-supporting. About 10% of devices.

Your device's classification is determined by its product code. The same physical device with different intended uses can fall into different classifications.

When 510(k) is the right path

510(k) is appropriate when all three conditions are met:

1. Your device is Class I or Class II
2. A legally marketed predicate exists with the same intended use
3. Any technological differences don't raise new questions of safety or effectiveness — or performance data can address them

If you can identify a strong predicate, 510(k) is almost always preferable to De Novo. De Novo is not a shortcut for avoiding difficult substantial equivalence arguments — it's for genuinely novel device types where no predicate can reasonably exist.

When PMA is unavoidable

PMA is required when your device is Class III and no reclassification or De Novo pathway is available. Signs you may be looking at a PMA:

• Your device is implantable and life-sustaining
• The device type has an explicit Class III designation in 21 CFR with no call for PMAs withdrawn
• FDA has previously declined to clear similar devices via 510(k) and required clinical data
• Your intended use involves a novel therapeutic mechanism with no safety precedent

The De Novo decision

De Novo is appropriate when your device is genuinely novel and presents low to moderate risk. Before pursuing De Novo, exhaust the predicate search. Regulatory consultants sometimes encounter devices that seem novel but have valid predicates under product codes the manufacturer hadn't considered. A thorough search across 175,000+ cleared devices is worth doing before committing to a De Novo strategy.

Pre-submission meetings

If pathway determination is genuinely ambiguous, request a Pre-Sub meeting with FDA. Pre-Sub meetings are free, typically scheduled within 90 days, and FDA's feedback is binding. This is particularly valuable for AI/ML-enabled devices, combination products, and devices with novel intended uses where classification precedent is thin.